Life Sciences

Life Sciences

Pharmaceuticals and medical technology help improve the quality of life for an increasing number of people. Medical treatments, instruments and aids are becoming more and more necessary as the population ages. The current trend is towards personalised medicines and technologies that, while highly effective, are expensive to develop. At the same time, large buyers are monitoring their costs, and changes to the distribution system for medicines are being debated.

The pharmaceuticals industry and the distribution of pharmaceuticals are guided by strict rules covering everything from R&D to marketing. The regulation of medical technology is also approaching that of the pharmaceuticals industry. When health and safety are at stake, it is vital to operate irreproachably.

We help pharmaceutical and medical technology companies secure their rights. We handle patent litigation and trials relating to authority decisions with years of experience. We have solid expertise in marketing law and procurement matters. The pharmacy industry is also one of our specialties, and we can provide pharmacies will full service in all legal matters.

Latest references

We successfully represented Arctic Biomaterials Oy before the Finnish Market Court in an extensive dispute concerning alleged patent infringement and invalidity of the patent-in-suit. Our client has invented next-generation bioabsorbable composites that are engineered with Arctic Biomaterials’ X3 bioactive natural mineral fibers, offering robust, bioactive reinforcement for orthopedic implants. These advanced composites empower customers to create high-strength bioabsorbable solutions for the most demanding applications. Back in 2019, Purac Biochem B.V. alleged, among other things, that our client’s Evolvecomp product had infringed Purac Biochem B.V.’s European patent validated in Finland protecting a biocompatible composite and its use. Purac Biochem B.V. filed a preliminary injunction against our client under the Act on Securing the Provision of Evidence in Civil Cases Concerning Industrial Property Rights and Copyright (344/2000). The Finnish Market Court issued an ex-parte injunction against our client on 2 April 2019 (MAO:150/19) and a final injunction on 19 February 2020 (MAO:59/20). Our client had disputed Purac Biochem B.V.’s patent infringement claim from the beginning and claimed that the patent-in-suit was invalid. After five years of litigation, the Finnish Market Court handed down a ruling in the joined invalidity and infringement cases on 10 October 2024 (MAO:560/2024 and MAO:561/2024) declaring Purac Biochem B.V.’s patent invalid and dismissing Purac’s infringement action against Arctic Biomaterials. Also, the preliminary injunction based on an alleged patent infringement imposed against Arctic Biomaterials was cancelled. The Market Court declared Purac Biochem B.V.’s patent invalid due to a lack of inventive step. The Market Court applied the could-would method for determining whether the patent-in-suit is inventive or not. The could-would method is based on determining whether a person skilled in the art would (not simply could, but would) have made a specific improvement to prior solutions, based on the available prior art. The Market Court ruled that it would have been obvious to a person skilled in the art to solve the objective technical problem of the patent-in-suit in the manner presented in claim 1, using as a starting point the closest prior art (prior patent publication) and combining it with the teaching of another prior art publication. The decision is final.
Case published 29.1.2025
We advised BYG4Lab, a portfolio company of the European growth buyout investor Keensight Capital, on its acquisition of Finbiosoft Oy, an innovative software company founded in 2011 with a mission to help laboratories reach higher quality and better efficiency. Founded in 1982, BYG4lab is a leading software company specialised in data management solutions for medical laboratories. The company is headquartered in France and employs nearly 110 people, of which approximately 40% are in R&D. Keensight Capital is a European growth buyout investor with deep expertise in technology and healthcare. Keensight Capital partners with the management teams of fast growing and profitable companies providing capital, strategic guidance and operational support.
Case published 14.3.2024
We advised Keensight Capital on the Finnish law aspects of the combination of Biovian and 3P Biopharmaceuticals, two leading biologics contract development and manufacturing organisations (CDMOs) backed by Keensight Capital, to establish 3PBIOVIAN, a new pan-European leader in its field. The combined group will offer unparalleled end-to-end development and manufacturing services for all protein expression systems and viral vectors, both for drug substance and drug product, from preclinical to clinical development and commercial phases. With over 500 professionals, manufacturing sites in Pamplona-Noáin (Spain) and Turku (Finland) and its commercial office in Boston (USA), 3PBIOVIAN will become one of the main independent European bio-CDMOs. We advised Keensight Capital alongside Paul Hastings, Keensight Capital’s lead legal counsel in the transaction, and Strelia and Garrigues, who, respectively, advised Keensight Capital on Luxembourgian and Spanish legal aspects of the combination.
Case published 6.2.2024
We advised Biovian Oy, a Finnish company, in a debt refinancing initiative and securing a new funding package with Eurazeo, a French investment company, to support GeneCity facility expansion. The package will be used to refinance existing debt and to finance investment in GeneCity. The GeneCity facility will house cutting-edge equipment and advanced technologies to support the development, manufacturing, and testing of ATMP (Advanced Therapy Medicinal Products). It will also feature dedicated Class A to D cleanroom areas for bulk drug substances as well as final drug product manufacture. The new viral vector facility building has been started in the autumn of 2023 and the facility is expected to be ready in 2025. The new funding package is an important milestone in Biovian’s growth journey and will support Biovian in continuing its strong organic growth. The GeneCity expansion is a strategic move aimed at meeting the growing demand for high-quality biopharmaceutical manufacturing services and further solidifying Biovian’s position as a trusted partner in the biopharmaceutical industry.
Case published 17.1.2024